LY3202626   Click here for help

GtoPdb Ligand ID: 11557

Synonyms: compound 22 [PMID: 34081466] | LY-3202626
PDB Ligand
Compound class: Synthetic organic
Comment: LY3202626 is a CNS-penetrant beta-secretase 1 (BACE1) inhibitor [2]. It was designed to mitigate ocular and liver toxicity problems that led to termination of previous clinical BACE1 inhibitor development programmes (LY2811376 and LY2886721 respectively).
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 9
Hydrogen bond donors 2
Rotatable bonds 6
Topological polar surface area 156.81
Molecular weight 498.14
XLogP 1.74
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES COc1c[n]c(c[n]1)C(=O)Nc1ccc(c(c1)[C@]12N=C(N)SC[C@@H]2CN(C1)c1[n]cc(c[n]1)F)F
Isomeric SMILES COc1c[n]c(c[n]1)C(=O)Nc1ccc(c(c1)[C@]12N=C(N)SC[C@@H]2CN(C1)c1[n]cc(c[n]1)F)F
InChI InChI=1S/C22H20F2N8O2S/c1-34-18-8-26-17(7-27-18)19(33)30-14-2-3-16(24)15(4-14)22-11-32(21-28-5-13(23)6-29-21)9-12(22)10-35-20(25)31-22/h2-8,12H,9-11H2,1H3,(H2,25,31)(H,30,33)/t12-,22-/m0/s1
InChI Key VQSRKMNBWMHJKY-YTEVENLXSA-N
References
1. Lo AC, Evans CD, Mancini M, Wang H, Shcherbinin S, Lu M, Natanegara F, Willis BA. (2021)
Phase II (NAVIGATE-AD study) Results of LY3202626 Effects on Patients with Mild Alzheimer’s Disease Dementia.
Journal of Alzheimer's Disease Reports, 5 (1): 321-336. DOI: 10.3233/ADR-210296
2. McKinzie DL, Winneroski LL, Green SJ, Hembre EJ, Erickson JA, Willis BA, Monk SA, Aluise CD, Baker TK, Lopez JE et al.. (2021)
Discovery and Early Clinical Development of LY3202626, a Low-Dose, CNS-Penetrant BACE Inhibitor.
J Med Chem, 64 (12): 8076-8100. [PMID:34081466]